No Data
Profit: Report for the third quarter of 2024
Guangdong VTR Bio-Tech (300381.SZ) released its performance for the first three quarters, with a net income of 42.7988 million yuan, an increase of 245.33%.
Guangdong VTR Bio-Tech (300381.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved a revenue of 6...
Guangdong VTR Bio-Tech (300381.SZ): net income in the third quarter was 1.0152 million yuan, a year-on-year decrease of 79.64%.
Guangdong VTR Bio-Tech (300381.SZ) announced its third quarter report for 2024 on October 22nd. During the reporting period, the revenue was 0.211 billion yuan, a decrease of 3.52% year-on-year. The net income attributable to shareholders of the listed company was 1.0152 million yuan, a decrease of 79.64% year-on-year. The net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was -4.832 million yuan. Basic earnings per share were 0.0021 yuan.
Guangdong VTR Bio-Tech Co., Ltd. (SZSE:300381) Held Back By Insufficient Growth Even After Shares Climb 41%
Shareholders 32% Loss in Guangdong VTR Bio-Tech (SZSE:300381) Partly Attributable to the Company's Decline in Earnings Over Past Three Years
Guangdong VTR Bio-Tech (300381.SZ): The controlling shareholder plans to reduce its shareholding by no more than 2.00% of the company's shares.
Guangdong VTR Bio-Tech (300381.SZ) announced on September 25th that the controlling shareholder, Zhuhai Jinda Investment Co., Ltd. (referred to as "Jinda Investment"), holds 151,767,378 shares of the company (31.67% of the total share capital after excluding the shares held in the company's repurchase special securities account). They plan to reduce their shareholding by no more than 9,580,000 shares (i.e., not exceeding the special securities repurchase account shares) through block trade within 3 months after 15 trading days from the date of this announcement (i.e., from October 24, 2024 to January 23, 2025).
Guangdong VTR Bio-Tech Co., Ltd. (SZSE:300381) Not Doing Enough For Some Investors As Its Shares Slump 27%
No Data
